BACKGROUND: A study was undertaken to examine the dose-response relation of inhaled fluticasone in adolescents and adults with asthma. METHODS: A meta-analysis was carried out of randomised clinical trials that presented data on at least one outcome measure of asthma and that used at least two doses of fluticasone given twice daily. The main outcome measures were forced expiratory volume in 1 second (FEV1), morning peak expiratory flow (amPEF), beta agonist use, and withdrawals due to exacerbations of asthma. RESULTS: Seven studies of 2431 adolescents and adults with moderate to severe asthma met the inclusion criteria for the meta-analysis. Four studies examined a dose of >500 microg/day. For all outcome measures there were no statistically significant differences between a dose of 200 v 500 microg/day, 500 v 1000 microg/day, and 200 v > or =500 microg/day, although the point estimates favoured the higher doses. The mean improvement for FEV1 and amPEF resulting from an increase in dose from 200 to > or =500 microg/day was 0.07 l (95% CI -0.01 to 0.14) and 5.9 l/min (95% CI -3.0 to 15.3), respectively. The odds ratio for withdrawals with 200 microg/day compared with > or =500 microg/day was 1.27 (95% CI 0.78 to 2.07). CONCLUSIONS: In adolescents and adults with asthma, most of the therapeutic benefit of fluticasone is achieved with a total daily dose of 200 microg/day with minimal further clinical benefit achieved with higher doses. This conclusion is qualified by the recognition that there is considerable individual variability in the response to inhaled corticosteroids in asthma, which would suggest that some patients may obtain a greater clinical benefit at higher doses.
BACKGROUND: A study was undertaken to examine the dose-response relation of inhaled fluticasone in adolescents and adults with asthma. METHODS: A meta-analysis was carried out of randomised clinical trials that presented data on at least one outcome measure of asthma and that used at least two doses of fluticasone given twice daily. The main outcome measures were forced expiratory volume in 1 second (FEV1), morning peak expiratory flow (amPEF), beta agonist use, and withdrawals due to exacerbations of asthma. RESULTS: Seven studies of 2431 adolescents and adults with moderate to severe asthma met the inclusion criteria for the meta-analysis. Four studies examined a dose of >500 microg/day. For all outcome measures there were no statistically significant differences between a dose of 200 v 500 microg/day, 500 v 1000 microg/day, and 200 v > or =500 microg/day, although the point estimates favoured the higher doses. The mean improvement for FEV1 and amPEF resulting from an increase in dose from 200 to > or =500 microg/day was 0.07 l (95% CI -0.01 to 0.14) and 5.9 l/min (95% CI -3.0 to 15.3), respectively. The odds ratio for withdrawals with 200 microg/day compared with > or =500 microg/day was 1.27 (95% CI 0.78 to 2.07). CONCLUSIONS: In adolescents and adults with asthma, most of the therapeutic benefit of fluticasone is achieved with a total daily dose of 200 microg/day with minimal further clinical benefit achieved with higher doses. This conclusion is qualified by the recognition that there is considerable individual variability in the response to inhaled corticosteroids in asthma, which would suggest that some patients may obtain a greater clinical benefit at higher doses.
Authors: Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793
Authors: M Lawrence; J Wolfe; D R Webb; P Chervinsky; D Kellerman; J P Schaumberg; T Shah Journal: Am J Respir Crit Care Med Date: 1997-09 Impact factor: 21.405
Authors: W W Busse; S Brazinsky; K Jacobson; W Stricker; K Schmitt; J Vanden Burgt; D Donnell; S Hannon; G L Colice Journal: J Allergy Clin Immunol Date: 1999-12 Impact factor: 10.793
Authors: S J Szefler; H A Boushey; D S Pearlman; A Togias; R Liddle; A Furlong; T Shah; K Knobil Journal: J Allergy Clin Immunol Date: 1999-05 Impact factor: 10.793
Authors: R A Pauwels; C G Löfdahl; D S Postma; A E Tattersfield; P O'Byrne; P J Barnes; A Ullman Journal: N Engl J Med Date: 1997-11-13 Impact factor: 91.245
Authors: T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie Journal: Clin Rev Allergy Immunol Date: 2015-02 Impact factor: 8.667
Authors: Karine L Clearie; Peter A Williamson; Karen Meldrum; Michael Gillen; Lars-Goran Carlsson; Marie Carlholm; Jan Ekelund; Brian J Lipworth Journal: Br J Clin Pharmacol Date: 2011-04 Impact factor: 4.335
Authors: Hengameh H Raissy; H William Kelly; Michelle Harkins; Stanley J Szefler Journal: Am J Respir Crit Care Med Date: 2013-04-15 Impact factor: 21.405